Ide-cel versus cilta-cel in multiple myeloma: a collaborative decision between patient and doctor

(1:33)

KarMMa-4: ide-cel for newly diagnosed high-risk multiple myeloma

(1:53)

Real-World CAR-T Outcomes, Use of Ide-cel, Cilta-cel for Myeloma

(7:55)

Proteomic profiles of CRS following treatment with liso-cel and ide-cel

(3:18)

CAR-T in multiple myeloma: cilta-cel \u0026 ide-cel

(50)

Ide-cel therapy for multiple myeloma with renal impairment

(1:43)

Safety, efficacy and tolerability of ide-cel in the real-world

(2:8)

Ide-Cel CART in Multiple Myeloma

(55)

Impact of age on ide-cel efficacy in the KarMMa trial

(1:55)

ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa results

(10:18)

What is ide-cel and how can it benefit myeloma patients?

(4:34)

Further improvements of ide-cel therapy in KarMMa trials

(59)

Secondary HRQoL domains in the KarMMa study of ide-cel in myeloma

(2:41)

Toxicities associated with ide-cel in KarMMa

(1:11)

CRB-401: ide-cel for R/R multiple myeloma

(5:5)

Enhanced health-related quality of life (HRQoL) with ide-cel treatment in patients with refracto...

(3:54)

The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment

(36)

The impact of extramedullary multiple myeloma on outcomes with ide-cel

(1:8)

Impact of ide-cel and future directions

(3:)

Real-world experience: ide-cel for R/R multiple myeloma

(1:28)